Transcriptional repression of the TGF-b type II receptor (RII) is one of the mechanisms leading to TGF-b resistance. The newly identi®ed epithelium-speci®c ets transcription factor ERT/ESX/ELF-3/ESE-1/jen binds to the TGF-b RII promoter and induces promoter activity. The human gastric cancer cell lines, which show undetectable level of TGF-b RII mRNA, do not express ERT mRNA. To study the molecular mechanisms of loss of ERT expression, we have cloned and characterized the human ERT promoter. DNA transfection experiments and electrophoretic mobility shift assays have revealed the existence of a distinct enhancer element (7186 to 7177) which we named ESE (ERT promoter speci®c element). Deletion of the ESE markedly decreased expression of the target gene. ESE interacts with two distinct nuclear protein complexes, at least one of which appears to be inactivated in a cell line which does not express the ERT mRNA, compared to a cell line expressing the ERT mRNA. These results suggest the possibility that inactivation of the sequence-speci®c DNA binding protein to the region from 7186 to 7177 contributes to the loss of ERT expression, leading to the loss of TGF-b type II receptor mRNA in human gastric cancer cell lines. Oncogene (2001) 20, 1235 ± 1245.
Introduction
Transforming growth factor-b (TGF-b) has been implicated in a wide variety of cellular processes, including regulation of the cell cycle, cell dierentiation, and extracellular matrix synthesis (Roberts and Sporn, 1990; MassagueÂ et al., 1994) . Inactivation of the TGF-b signaling pathway contributes to malignant transformation, and can occur through one of several mechanisms involving mutation or transcriptional repression of either receptors or intermediates in the signal transduction pathway (MassagueÂ , 1998; Reiss, 1997; Kim and Kim, 1996; Markowitz and Roberts, 1996) .
TGF-b primarily exerts its biological eects through interactions with TGF-b type II receptor (RII) (Lin et al., 1992; Wrana et al., 1994) . Ligand binding to TGFb RII induces recruitment of TGF-b type I receptor (RI) into stable complex, resulting in signal transduction to downstream factors such as Smad proteins. Abnormality of TGF-b RII causes the block of initial step of signal transduction cascades by TGF-b and this decreased responsiveness of TGF-b may play an important role in the process of carcinogenesis (Park et al., 1994; Myero et al., 1995) . Much work has recently demonstrated a high correlation between defects in TGF-b RII expression and TGF-b resistance in various cancer cell lines. We have found a signi®cant correlation between structural abnormalities in the TGF-b RII gene and the development of TGF-b resistance in a subset of human gastric cancer cell lines (Park et al., 1994; Myero et al., 1995; Chang et al., 1997b; Yang et al., 1999) . Frame shift mutations within a 10 bp polyadenine repeat present in the TGFb RII coding region frequently occur in cells with microsatellite instability or replication errors (RER+), leading to premature termination of the receptor protein Myero et al., 1995) . In addition, it is reported that transcriptional repression of TGF-b RII gene may be another mechanism leading to TGF-b resistance (Park et al., 1994; Kadin et al., 1994; Horie et al., 1998; Hougaard et al., 1999) . Transformation of cells by the product of the adenovirus E1A gene (Missero et al., 1991; Kim et al., 1997) , or overexpression of cyclin D1 (Okamoto et al., 1994) in epithelial cells, has been associated with downregulation of TGF-b RII expression and TGF-b resistance. We have recently reported that Ewing sarcoma EWS-FLI-1 fusion gene suppresses transcription of TGF-b RII gene . These results strongly suggest that both transcriptional regulation of TGF-b RII expression and loss of function of TGF-b RII play an important role in modulating TGF-b responsiveness.
Our laboratory have cloned the epithelial-speci®c ets family transcription factor, ERT/ESX/ESE-1/ELF-3/ jen (Choi et al., 1998; Chang et al., 1997a; Oettgen et al., 1997; Tymms et al., 1997; Andreoli et al., 1997) , which binds to the second positive regulatory element of the TGF-RII promoter, and we have shown that ERT induces TGF-b RII promoter activity. These results suggest that ets family members may be the major transcriptional factors involved in the regulation of TGF-b RII gene expression. Several groups have reported that ERT/ESX/ESE-1/ELF/jen is involved in transactivation of endo-A/keratin-8, transglutaminase 3, SPRR2A, and pro®laggrin as well as TGF-b RII, and associated with mammary gland development and involution (Choi et al., 1998; Andreoli et al., 1997; Neve et al., 1998) . Ets transcription factors had been originally identi®ed as oncogene and the Ets gene family currently consists of approximately 30 members, playing a role in fundamental processes as cell growth, dierentiation, developmental programs, viral infection cycles and malignant transformation (Macleod et al., 1992; Watson et al., 1992) .
The observation that ERT induces TGF-b RII expression suggests the possibility that the regulation of ERT gene plays an important role in the expression of TGF-b RII gene (Choi et al., 1998; Chang et al., 1999) . To understand the mechanisms underlying the regulation of expression of ERT, we characterized the promoter region of the ERT gene in human gastric cancer cell lines. In this study, we have examined the ERT promoter activity in two human gastric cancer cell lines, the SNU16 cell line which expresses TGF-b RII mRNA and the SNU1 cell line which does not express TGF-b RII mRNA. SNU1 cell line bears one TGF-b RII allele with a 71 frameshift and does not respond to TGF-b. Even though SNU1 cell lines exhibit RER+ phenotype and bear mutations within TGF-b RII polyadenine repeat , we assumed that the transcriptional machinery controlling the expression of TGF-b RII gene is intact. We ®rst examined the control of ERT gene expression and characterized the element within its promoter that contributes to ERT gene expression in human gastric cancer cell lines. Second, we showed that binding factors to the element, which is important for activity of the ERT promoter, are distinguished in the cells with or without the expression of TGF-b RII gene.
Results
Expression of the ERT gene plays an important role in the expression of TGF-b RII gene in human gastric cancer cell lines Previously, we have shown that some human gastric cancer cell lines do not express the TGF-b RII (Park et al., 1994) . To see whether loss of TGF-b RII expression correlates with loss of ERT expression, we performed Northern blot analysis for human gastric cancer cell lines. The SNU16 and SNU620 cell lines, which express TGF-b RII mRNA, also express ERT mRNA, but the SNU1, SNU484, and SNU668 cell lines, which do not express TGF-b RII mRNA, do not express ERT mRNA (Figure 1 ). However, another ets transcription family member, ERF, is expressed in all cell lines.
Our previous study has shown that ERT induces TGF-b RII promoter activity in HepG2 human hepatoblastoma cells and Hs587t human breast cancer cells (Choi et al., 1998; Chang et al., 1999) . However, the correlation between the expression of ERT and that of TGF-b RII gene was detected only in human gastric cancer cell lines (Figure 1 and unpublished observation). Therefore, we examined whether ERT also induces TGF-b RII activity in SNU1 and SNU16 human gastric cancer cells. When the TGF-b RII promoter (pTbRIIP7219/+36)-luciferase reporter, showing the strongest promoter activity (Bae et al., 1995) , was cotransfected with the ERT expression vector, TGF-b RII promoter activity was induced fourfold in SNU1 cells (Figure 2a ). When these constructs were transfected into SNU16 cells, TGF-b RII promoter activity was induced ®vefold as well (data not shown). Previously, we have shown that ERT protein binds to ETS binding site, which is present in the second positive regulatory element (PRE2), and plays an important role in RII expression (Choi et al., 1998) . To con®rm whether ERT protein transactivates PRE2 element in human gastric cancer cell lines, we have generated luciferase reporter constructs, which only contain the PRE2 by inserting double-stranded Figure 1 Expression of TGF-b RII and ERT in human gastric cancer cell lines. Northern blot analysis of the expression of TGFb RII and ERT genes was performed in several human gastric cancer cell lines. Total RNAs were isolated from gastric cancer cell lines including SNU1 and SNU16 cells. A 1.5 kb fragment of TGF-b type II receptor gene, a 1.5 kb of ERF gene, and a l.2 kb ORF region of ERT gene were used as probes. The GAPDH gene was used as an internal control oligonucleotides into the E4D38-luciferase vector. We have previously shown that mutation of nucleotides +16 to +20 (M4) in the PRE2 abolishes PRE2 enhancer activity (Choi et al., 1998) . The level of luciferase expression by the PRE2 WT-E4D38-luc construct was increased fourfold in SNU1 cells by ERT, whereas there was no induction of the PRE2 M4-E4D38-luc construct (Figure 2b ). These results suggest that ERT is responsible for the induction of TGF-b RII gene expression in these human gastric cancer cell lines.
Isolation and characterization of the promoter region of the human ERT gene
Since ERT is responsible for TGF-b RII promoter expression in human gastric cancer cell lines, and cell lines that lack TGF-b RII expression do not express ERT, we ®rst examined the structure of ERT genome in SUN1 human gastric cancer cells. Southern hybridization showed that this cell line does not have any structural abnormalities of ERT gene (data not shown). This result prompted us to study the regulation of ERT gene expression. Therefore, we isolated the 1.9 kb human ERT promoter fragment using a Human Genome Walker Kit (Clontech, Palo Alto, CA, USA). The complete sequence of the 1.8 kb human ERT promoter fragment was determined by the dideoxy sequencing method (Genbank Accession AF287266). Comparison of the nucleotide sequence of the ERT promoter to the recently reported ESX/ ESE-1/LEF/jen promoter (Neve et al., 1998; Oettgen et al., 1999) was identical but the 1.9 kb ERT promoter revealed an additional 1500 nucleotides at the 5' end ( Figure 3 ). We examined the 5' end of the human ERT mRNA through 5' RACE PCR. The transcriptional start site determined by the 5' RACE PCR method is assigned to nucleotide C, as indicated in Figure 3 . This transcription start site is one nucleotide upstream of the previous reports (Neve et al., 1998; Oettgen et al., 1999) . However, we cannot rule out the possibility of multiple sites.
Identification of the positive regulatory elements in the human ERT promoter
In order to identify sequences essential for transcription of the human ERT gene, progressively shorter fragments of the 5'-¯anking region fused with the coding region of the luciferase gene in the plasmid pGL3-basic (Promega) were transfected into SNU1 and SNU16 cells ( Figure 4 ). As seen in Figure 4b , the longest promoter construct, hERTp7877/+122 showed strong promoter activity compared to the vector alone in SNU16 cells whereas this construct revealed low promoter activity in SNU1 cells. Basal activity of hERTp7877/+122 is 60-fold higher in SNU16 cells than in SNU1 cells. In addition, phERTp7218/+122, which showed the strongest promoter activity in SNU16 cells, was little expressed (29), was cotransfected with the ERT expression vector into SNU1, a human gastric cancer cell line, which does not express ERT mRNA. (b) One copy of the PRE2 sequence from +2 to +36 was linked to adenovirus E4 minimal promoter (738/+36)-luciferase reporter construct. WT shows the wild type sequence. M4 possesses the same sequence except for 5-nucleotide substitution of ETS binding site (+16 to +20). These chimeric constructs were contransfected with ERT expression vector into the SNU1 gastric cancer cell line, harvested 48 h after transfection, and assayed for luciferase activity. Results are averages of at least triplicate experiments of three independent transfections. Activities were normalized on the basis of b-galactosidase expression in all luciferase reporter experiments in SNU1 cells. Comparison of the activity of the ERT promoter between two cell lines suggests the possibility that the transcriptional mechanism of the ERT gene may be dierently regulated in these cell lines. In SNU16 cells, the hERTp7286/+122 deletion construct showed lower luciferase activity than the hERTp7246/+122 construct, suggesting the presence of a negative regulatory element in the 7286 to 7246 region. Deletion of the sequences between 7218 and 7186 reduced promoter activity signi®cantly, suggesting the presence of a positive regulatory element in this region. Interestingly, when the promoter was deleted to 7177, the activity of the hERT promoter was dramatically decreased about eightfold compared to hERTp7246/+122 construct ( Figure 4b ). The promoter activity of hERTp7186/+122 and hERTp7177/ +122 was very similar in the SNU1 cells whereas the promoter activity of hERTp7177/+122 was signi®-cantly decreased compared to that of hERTp7186/ +122 in SNU16 cells (Figure 4b ). This result indicates that the region from 7186 to 7177 acts as a strong enhancer element for the expression of the ERT gene in SNU16 cells but this strong enhancer is not functioning in SNU1 cells. Although we cannot exclude the possibility that other upstream regions from 7186 do not act as enhancer elements in SNU1 cells, our results show that the region from 7186 to 7177 is one of the elements responsible for dierential expression of the ERT gene in human gastic cancer cell lines.
The region from 7186 to 7177 in hERT promoter plays a critical role in the expression of the ERT gene of human gastric cancer cell line
To con®rm that the region from 7186 to 7177 plays an important role in the expression of the ERT promoter, the internal deletion mutants of this region were constructed and transfected into SNU16 cells ( Figure 5 ). Both deletions (hERTp7286/+122-DESE and hERTp7218/+122-DESE) reduced expression of the ERT promoter to the level of hERTp7177/+122, demonstrating that this region functions as a strong enhancer element in the expression of the ERT gene.
Next, we further characterized the sequences between 7186 to 7177, named as ESE (ERT promoter speci®c element). This sequence does not match any published binding site for previously described transcription factors. The plasmid ESE-WT-E4D38-luc, ESE-M1-E4D38-luc, and ESE-M2-E4D38-luc were generated by inserting double-stranded oligonucleotides into the E4D38-luc vector. ESE-WT contains wild type sequence of ESE element, and ESE-M1 and ESE-M2 indicate mutations of ESE element. Each mutant oligonucleotide contained a 4-base pair substitution in which pyrimidine pairs were converted to purine pairs and vice versa. These constructs were transfected into SNU16 cell lines. The level of luciferase expression by the ESE-WT-E4D38-luc was increased 3.5-fold compared to the E4D38-luc vector. The level of luciferase expression by the ESE-M2-E4D38-luc was slightly higher than the E4D38-luc vector, whereas the level of luciferase expression by ESE-M1-E4D38-luc was signi®cantly decreased (Figure 6a ). This result suggests that the sequence from 7186 to 7183 is essential to activity of the ESE element and the nuclear proteins recognizing the 7186 to 7183 region are presumably responsible for the expression of the ERT gene. Also, the result of luciferase assay with these constructs shows that the sequences from 7186 to 7177 are required for the maximum expression of the ERT gene. Finally, we examined the possibility that loss of the expression of the ERT gene in SNU1 cells may be due to the defect of transcription mediated by ESE element of human ERT promoter. Therefore, the ESE-WT-E4D38-luc construct was transfected into SNU1 and SNU16 cells together with b-galactosidase expression vector. The luciferase activity of the ESE-WT-E4D38-luc construct is higher compared to that of the vector (E4D38-luc) only in the SNU16 cells, but there was no change in luciferase activity in the SNU1 cells ( Figure  6b ). b-galactosidase activity showed a similar level in two cell lines. This result strongly suggests that the region from 7186 to 7177 and its binding factor(s) are one of the elements responsible for dierential regulation of the activity of the ERT promoter in human gastric cancer cell lines. Characterization of nuclear factors to the ESE element of the ERT promoter in human gastric cancer cell lines Several transfection experiments indicate that the region from 7186 to 7177 (ESE element) plays an important role in the expression of the ERT gene depending on gastric cancer cell types. To identify any dierence of nuclear proteins associated with sequences between 7186 and 7177 according to cell types, EMSA was performed as described above using a 32 Plabeled double-strand oligonucleotide containing these sequences. The reaction mixture was electrophoresed on a polyacrylamide gel and viewed by autoradiography. The results show that four bands (complexes a, b, c, d) in SNU1 cells and one strong band (complex a) in SNU16 are visualized as well as multiple fainter bands. (Figure 7) . Multiple fainter bands appear to be nonspeci®c because the addition of non-speci®c competitors causes the disappearance of the bands. In the absence of unlabeled competitor oligonucleotide (Figure 7a, lanes 1, 3 and 5) , one strong lower band (complex d) and three weak upper bands (complexes a, b, and c) are apparent in SNU1 nuclear extract. Complex d is not present in SNU16 nuclear extract but in HepG2 nuclear extract. Interestingly, complex a is very strong in SNU16 nuclear extract compared to SNU1 and HepG2 nuclear extracts, whereas complexes b and c are not present in SNU16 nuclear extract (Figure 7a,b, lane 3) . This result indicates that the nuclear protein forming complex a may be highly activated in SNU16 cell lines, leading to the expression of ERT gene. However, we cannot exclude the possibility that the proteins forming complexes b, c, or d, which is only present in SNU1 cells, function as a repressor. And these nuclear proteins which recognize sequences between 7186 and 7177 are not present in the nuclear extracts of primary human foreskin ®broblasts (Figure 7 , lane 5), suggesting that these nuclear proteins might be epithelial-speci®c DNA binding proteins. Since it is reported that ERT gene is only expressed in epithelial cells, the presence of these binding proteins can demonstrate speci®city of the expression of the ERT gene.
Complex a recognizes the sequence from 7186 to 7183 and plays an essential role in the expression of the ERT promoter mediated by ESE element
To determine which sequences within the 7186 to 7177 region of the human ERT promoter are required for speci®c binding to several complexes and are important for the expression mediated by ESE element, we used two mutant oligonucleotides, M1 and M2, derived from the sequences between 7186 and 7177 (Figure 6a) . A mobility shift assay was then performed using a radiolabeled ESE element probe incubated with either SNU1 or SNU16 nuclear proteins in competition with two mutant oligonucleotides.
In the case of SNU1 cells, substitution of nucleotides 7186 to 7183 (Figure 8a , lane 5, ESE-M1) is unable to compete for binding to complexes a and c whereas the intensity of complexes b and d was slightly decreased (Figure 8a, lane 5) . The level of competition was similar to that of the non-speci®c competitor (Figure 8a, lane 4) . This result shows that complexes a and c are speci®c to the sequence from 7186 to 7183 and the interaction of complexes b and d is weak or nonspeci®c. Mutation of nucleotides 7182 to 7179 (M2 mutation) is able to compete with complex a, but not with complex c, suggesting that complex c is also speci®c to the sequence from 7182 to 7179 ( Figure  8a , lane 6). To con®rm these results described by competition assay, we also performed EMSA using radiolabeled ESE-WT, ESE-M1, and ESE-M2 oligonucleotides. Complexes a, b, and c did not bind to M1, but complexes a and b bound to M2 using nuclear extract of SNU1 cell line (Figure 8b, lanes 3 and 4) . Taken together with competition, the result of gel shift assay with mutant oligomers indicates that the protein forming complex a is speci®c to the sequence from 7186 to 7183 and complex c binds to the region to both sequences.
In SNU16 nuclear extract, ESE-M2 competed with complex a, but ESE-M1 failed to compete (Figure 8c , lanes 5 and 6). Complex a is able to bind to radiolabeled ESE-M2 but not to ESE-M1 (Figure 8d , lanes 3 and 4), demonstrating that complex a is speci®c to the region from 7186 to 7183 (ESE-M1). These competition patterns of complex a in SNU16 cells is similar to that in SNU1 cells.
We already showed that the sequence from 7186 to 7183 (ESE-M1) plays a critical role in the expression mediated by ESE element (Figure 6 ). These results suggest that the highly activated nuclear protein (complex a) recognizing the 7186 to 7183 region may be responsible for the expression of the ERT gene in SNU16 cells. In addition, these results shows that the dramatically decreased intensity of complex a in SNU1 cells, compared to SNU16 cells, may contribute to the loss of the expression of the ERT gene on the transcriptional level. On the contrary, we do not exclude the possibility that complex d, which is only present in SNU1, acts as a repressor for the ESE element of the ERT promoter.
Discussion
Numerous other malignancies have been examined and individual tumors have been found to have developed resistance to growth inhibition by TGF-b (Park et al., 1994; Markowitz et al., 1995; Myero et al., 1995) . These tumors possess reduced or undetectable levels of receptors for TGF-b. Several lines of evidence suggest that transcriptional repression of the TGF-b RII gene may be a major mechanism to inactivate TGF-b RII (Park et al., 1994; Kadin et al., 1994; Horie et al., 1998; Hougaard et al., 1999; Hahm et al., 1999) . A series of Figure 6 Characterization of the strong positive element (7186 to 7177) of ERT promoter. (a) One copy of the region from 7189 to 7167 was linked to adenovirus E4 minimal promoter (738/+36)-luciferase reporter construct. This region contains the strong positive element from 7186 to 7177, named as ESE, for the expression of ERT promoter. WT shows the wild type sequence. M1 and M2 indicate the same sequences except for a 4-nucleotide substitution. These chimeric constructs were transfected into SNU16 cells, which were harvested 48 h after transfection and assayed for luciferase activity. (b) ESE-WT-E4D38-luc and control vector (E4D38-luc) were transfected into SNU1 and SNU16 cells to compare the activities mediated by ESE element in both cell lines. To normalize transfection eciencies in two cell lines, b-gal expression vector was also cotransfected into the cell lines. Results are averages of triplicate experiments of three independent transfections gastric cancer cell lines in which resistance to TGF-b correlated with genetic changes in the TGF-b RII gene were described (Park et al., 1994; Myero et al., 1995; Chang et al., 1997b; Yang et al., 1999) . Further analysis revealed that these cells express low to undetectable levels of expression of TGF-b RII. Since Hagan et al. (1995) have demonstrated that frameshift mutations located in the 5' half of mRNA transcripts are associated with decreased mRNA stability, it is possible that the TGF-b RII mRNAs with mutations are unstable. Alternatively, as demonstrated in this study, a transcriptional repression may also contribute to the inactivation of TGF-b RII gene expression.
The SNU1 human gastric cancer cell line contains a mutation in TGF-b RII polyadenine tract . The SNU1 cell line bears one TGF-b RII allele with a 71 frameshift and one allele that is wild type within the polyadenine tract. Because this cell line expresses an undetectable level of TGF-b RII mRNA, it is possible that the opposite allele is also altered. A complete sequencing of this allele may be necessary to verify this hypothesis. In addition to genetic changes, the results of the present study indicate that abnormalities in the transcriptional regulation of the TGF-b RII gene may also be involved in the inactivation of TGF-b RII gene expression.
Using a yeast one-hybrid system, we have isolated a new epithelium-restricted member of the ets family of transcription factors, ERT/ESX/ESE-1/ELF3/jen (Choi et al., 1998; Chang et al., 1997a; Oettgen et al., 1997; Tymms et al., 1997; Andreoli et al., 1997) , from human placenta cDNA library. ERT induced greater TGF-b RII promoter activity (Choi et al., 1998) . Among the cancer cell lines examined, a signi®cant correlation between the expression patterns of TGF-b RII mRNA and that of ERT mRNA was only observed in human gastric cancer cell lines. Previously, it has been reported that the overexpression of ERT induces endogenous TGF-b RII gene expression and restores the TGF-b responsiveness in human breast cancer cells . However, our unpublished observations have shown that the expression of ERT does not correlate with the expression of TGF-b RII gene in human breast cancer cells; the expression of another member of the ets family of transcription factors is correlated with that of TGF-b RII gene in human breast cancer cells. Taken together, these observations suggest that ERT regulates TGF-b RII expression in a tissuespeci®c manner.
To elucidate the molecular mechanism of loss of ERT expression, we isolated the promoter region for the human ERT gene. The sequencing data for the human ERT promoter region agree well with a previously published report and also extends the known sequence additional 600 base pairs upstream. The human ERT promoter contains a typical TATA box located at 728 nucleotide upstream of the apparent transcription start site. Sequence analysis reveals multiple sites homologous to known transcription factor consensus sequences. Two putative CACCC sequences for Kruppell-like factor binding site are located at 7273 and 7215. A putative Oct-1 binding site is recognized at 7119, ETS binding site at 783 and CCAAT box at 768.
Our results show that the human ERT promoter contains one strong enhancer element (7186 to 7177), which is responsible for dierential regulation of the ERT promoter in human gastic cancer cell lines. The strong enhancer element (7186 to 7177) is required for transcriptional activity because its deletion reduces the ERT promoter activity signi®cantly. Gel shift assay shows that this region may be the binding element to epithelium-speci®c nuclear factors. However, we cannot exclude the possibility of another positive regulatory element in the region from 766 to +122 since the basal promoter activity of this region is higher than that of the vector only. Our evidence shows that this region from 7186 to 7177, named as the ESE element, is important for the expression of the ERT gene depending on the types of human gastric cancer cell lines. In the SNU1 cell line that lacks the expression of the ERT gene, luciferase activity mediated by ESE element is not detected compared to the SNU16 cell line.
Gel retardation experiments using nuclear extracts of SNU1 and SNU16 cell lines demonstrate that complex a double-stranded oligonucleotides incubated with SNU1, SNU16, HepG2, or normal human foreskin ®broblast nuclear extract. Speci®c DNA-protein complexes identi®ed in SNU1, SNU16, and HepG2 nuclear extracts are not present in the nuclear extract of the normal human foreskin ®broblast is strongly activated only at SNU16 cell lines, expressing ERT mRNA, compared to the SNU1 cell line. This complex a requires the sequence from 7186 to 7183 for speci®c binding and the mutation of this region decreases the luciferase activity to basal level. Based on these results, nuclear protein(s) forming complex a is very important for the expression of the ERT gene, suggesting the possibility that this protein is highly activated in the SNU16 gastric cancer cell line. That is, the inactivation or decrease of this protein forming complex a contributes the loss of the ERT gene expression in the SNU1 cell line. The ESE element and its binding factor forming complex a play an important role in dierential expression of the ERT gene in human gastric cancer cell lines. However, we do not exclude the possibility that one of the complexes b, c, and d, which is present in the SNU1 cell line, functions as repressor, even though the binding activities of complexes b and d are weak or nonspeci®c.
ERT/ESX/ESE-1/ELF3/jen is located at chromosome 1q32 in a region known to be ampli®ed in 50% of early breast cancers and overexpressed in HER2/neu activated breast cancer cells (Chang et al., 1997a; Tymms et al., 1997; Oettgen et al., 1999) . This gene is overexpressed at an early stage of human breast cancer development known as ductal carcinoma in situ (DCIS). However, the role of ERT/ESX/ESE-1/ ELF3/jen during the mammary carcinogenesis is not known. ERT/ESX/ESE-1/ELF3/jen is repressed during lactogenesis and then dramatically up-regulated with weaning and initiation of mammary gland involution (Neve et al., 1998) . ERT expression is markedly decreased when mouse and rat mammary epithelium is terminally dierentiated in vivo into milk-producing lobuloalveolar unit (Andreoli et al., 1997) . However, ERT is exclusively expressed in the most terminally dierentiated forms of epidermal keratinocytes. These reports imply that the expression of the ERT gene is highly regulated depending on cell types or cell stages. Based on our results, it is possible that these regulations are mediated by ESE element and its binding proteins.
Recently, several genes regulated by ERT were identi®ed. Transglutaminase 3 (TGM3) (Andreoli et al., 1997) and TGF-b RII (Choi et al., 1998) are transcriptionally up-regulated by ERT. The activity of TGM3 promoter is induced by ERT. Recently, we have demonstrated that overexpression of ERT by infecting Hs587t human breast cancer cell lines with a retroviral construct expressing ERT induced higher levels of endogenous TGF-b RII mRNA and protein expression relative to cells infected with chloramphenicol acetyltransferase (CATneo) as a control . Relative to control cells, the ERTneoexpressing Hs578t cells show approximately a 50% reduction in cell growth in the presence of exogenous TGF-b, suggesting that ERT plays an important role as a transcriptional activator of TGF-b RII expression, and that deregulated ERT expression may play a critical role in rendering Hs578t human breast cancer cells insensitive to TGF-b's negative growth eects.
In conclusion, this study has shown that the promoter region of the human ERT gene contains the strong enhancer element responsible for dierential regulation of the ERT promoter in human gastric cancer cell lines. Multiple nuclear proteins have been shown to bind speci®cally to this enhancer element and one of the nuclear proteins interacting with this enhancer element, complex a, is highy activated in the human gastric cancer cell line which expresses the ERT mRNA, not the SNU1 gastric cancer cell line, suggesting that loss of ERT expression may be due to the reduced expression of the speci®c transcription factor or inactivation.
Materials and methods

Cloning of human ERT promoter fragment
Isolation of the 1.9 kb human ERT promoter fragment was performed with a Human Genome Walker Kit purchased from Clontech according to the manufacturer's instructions.
Cell culture, transfections and reporter assays
Human gastric cancer cell lines, SNU1 and SNU16, were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum. HepG2 cell and primary human foreskin ®broblast cells were grown in minimal essential medium and Dulbecco's modi®ed Eagle's medium supplemented with 10% fetal bovine serum, respectively. For transient transfections, 3610 6 cells were plated in each well of a 6-well dish and transfected using lipopectin reagent (GIBCO ± BRL) according to manufacturer's protocol. Cells were harvested 48 h after transfections. Luciferase activity was determined in the cell lysate using an assay kit (Analytic Luminescence Lab. Ann Arbor, MI, USA) and a Dynatech Laboratories ML3000 microtiter plate luminometer. All experiments were repeated at least three times with similar results. Activities were normalized on the basis of b-galactosidase expression from pSV-b-galactosidase in all luciferase reporter experiments.
Plasmids and oligonucleotides
TGF-b RII promoter-luciferase constructs were described previously (Choi et al., 1998) . Deletion mutants of ERT promoter shown in Figure 4 were cloned into the promoterless luciferase vector (pGL3-basic) using HindIII and SacI sites. The sequences of the PCR-generated portions of all constructs were veri®ed by DNA sequencing. To construct the internal deletion mutants of the region from 7186 to 7177 shown in Figure 5 , the region from 7286 to 7186 was ampli®ed using oligonucleotides (5'-GGGGTACCACA-GATGCCCACCCCAGCAA-3' and 5'-CCGCTCGAGAT-GATTGTCAGAGTCTGTCA-3') and cloned into KpnI ± XhoI of hERTp7177/+122. Double stranded oligonucleotide from 7218 to 7186 (5'-CGTGCGGGATGACA-GACTCTGACAATCATC-3') was also cloned into KpnI ± XhoI sites of hERTp7177/+122, resulting in hERTp7218/ +122-DESE. The sequences of two internal deletion mutants were veri®ed by DNA sequencing. The following double stranded oligonucleotides containing the regions from 7186 to 7177 were synthesized for use in the construction of reporter plasmids and EMSA. Underlined nucleotides have been changed from the wild type sequences. Only the sense sequences of each pair are listed here: ESE-WT (5'-AAACCAGCCGGGCCTGATTTCCC-3'); ESE-M1 (5'-AAAAACTCCGGGCCTGATTTCCC-3'); ESE-M2 (5'-AAACCAGAATTGCCTGATTTCCC-3'). Double stranded oligonucleotides, wild type (ESE-WT) and its mutants (ESE-M1 and ESE-M2) were cloned into NheI and XhoI sites of adenovirus E4 minimal promoter (738/+38)-luciferase reporter construct to examine its role in the expression of the ERT promoter. Oligonucleotides of PRE2 and its M4 mutation of TGF-b RII promoter, previously described (Choi et al., 1998) , were also cloned into NheI and XhoI sites of E4 minimal promoter (738/+38)-luciferase reporter construct for luciferase assay. To con®rm whether ERT protein activates type II receptor promoter in human gastric cancer cell lines, the plasmid pCDNA3.1-ERT was used for the expression of the ERT gene (Choi et al., 1998) .
Northern blot analysis
Total RNAs were isolated with TRIZOL reagent (GIBCO ± BRL) according to manufacturer's protocol. To detect the human type II receptor and ERT transcripts, a 1.5 kb fragment of human TGF-b type II receptor gene and cDNA of human ERT gene (Choi et al., 1998) were labeled by PRIME-IT random primer labeling kit purchased from Stratagene.
Nuclear extracts
Nuclear extracts of human gastric cancer cell lines were prepared as described (Bae et al., 1995) with minor modi®cation. Cells were harvested by centrifugation, washed in cold phosphate-buered saline, and incubated in two packed cell volume of buer A (10 mM HEPES, pH 8.0, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM dithiotreitol, 1 mM phenylmethanesulfonyl¯uoride, 16 protease inhibitor mix (Sigma), and 0.5% Nonidet P-40) for 5 min at 48C. The crude nuclei released by lysis were collected by microcentrifugation, rinsed twice in buer A, resuspended in 2/3 packed cell volume of buer C (20 mM HEPES pH 7.9, 1.5 mM MgCl 2 , 420 mM NaCl, 0.2 mM EDTA, 1 mM phenylmethanesulfonyl¯uoride, 16 protease inhibitor mix). Nuclei were incubated on a rocking platform at 48C for 30 min and clari®ed by microcentrifugation for 5 min. The resulting supernatants were diluted 1 : 1 with buer D (20 mM HEPES pH 7.9, 100 mM KCl, 0.2 mM EDTA, 20% glycerol, 1 mM dithiothreitol, 1 mM phenylmethane sulfonyl¯uoride, 16 protease inhibitor mix).
EMSA
Three oligonucleotides, ESE-WT, ESE-M1 and ESE-M2 were labeled with g-32 P-ATP and polynucleotide kinase. The fragments were then gel puri®ed using 10% polyacrylamide gel. Binding reactions contained 8 mg of nuclear extract protein, buer (10 mM Tris, pH 7.5, 50 mM NaCl, 1 mM dithiothreitol, 1 mM EDTA and 5% glycerol), 1.5 or 2 mg poly (dI-dC), and 30 000 c.p.m. of 32 P-labeled DNA in a volume of 20 ml reactions were incubated at room temperature for 20 min. For competition assay, unlabeled oligonucleotides of each oligomer were added to binding reactions as competitors. Binding reactions were electrophoresed on a 6% nondenaturating polyacrylamide gel at 180 V for 2 h in 0.56TBE buer and subjected to autoradiography.
Abbreviations TGF-b, transforming growth factor-b; TGF-b RII, TGF-b type II receptor; EMSA, eletrophoretic mobility shift assay; PCR, polymerase chain reaction; RACE, rapid ampli®cation of cDNA end.
